Safety & Effectiveness of the BEAM Device in Mild-to-moderate Acne

Completed · Not applicable

Conditions studied: Acne

In brief

This study will determine if the use of the BEAM device reduces the signs and symptoms of mild-to-moderate acne.

Key facts

Study ID

NCT01162837

Run by

Oregon Aesthetic Technologies

People needed

33

Starts

2010-06-01

Expected to finish

2010-10-01

Last updated by the study team

2012-05-03

Who can join

Age: 15 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 15 years or older of either gender and of any racial/ethnic group.
• At least 8 acne inflammatory lesions (see section 9) in the treatment and control areas.
• Presence of clinically-evident facial acne of mild-to-moderate severity (score 2-4 on the Global Acne Severity Scale, see below)
• Subjects must be in generally good health.
• Subjects must be able and willing to comply with the requirements of the protocol.

You may not qualify if…

• Oral retinoid use within six months of entry into the study.
• Systemic acne therapies (oral antibiotics) within 2 weeks of entry into the study.
• Topical acne therapies (retinoids, antibiotics) within 1 week of entry into the study.
• Microdermabrasion or superficial chemical peels at the site to be treated within 2 months of entry into the study.
• Subjects with a history of dermabrasion or laser resurfacing at the site to be treated.
• Use of topical lipid absorbing substances (Clinac AC) within 1 week of entry into the study.
• Non-compliant subjects.
• Subjects with a significant medical history or concurrent illness/condition which the investigator(s) feel is not safe for study participation.
• Subjects using alcohol-based topical solutions or "exfoliating" agents within 1 week of entry into the study.
• Subjects with a history of very frequent herpes simplex infections of the face or with clinical evidence of active herpes simplex infections.
• Pregnant or nursing females.
• Subjects with known photosensitivity disorders felt by the investigators to preclude safe inclusion in the study.
• Subjects who have a history of significant post-inflammatory hyperpigmentation at the sites of acne lesions.

Where it is running

• Baumann Cosmetic & Research Institute — Miami Beach, Florida, United States
• Grekin Skin Institute — Warren, Michigan, United States
• Oregon Dermatology & Research Institute — Portland, Oregon, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.